Today's Breaking News

CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma Read more

FDA approves Lumakras® (sotorasib) in combination with Vectibix® (panitumumab) for chemorefractory KRAS G12C-mutated metastatic colorectal cancer Read more

Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence Read more

Latest R&D and Business News

17 January 2025

Avacta Announces Positive New Data from the AVA6000 Phase 1 trial Demonstrating Clinically Meaningful Tumor Shrinkage in Patients with Salivary Gland Cancers

17 January 2025

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

17 January 2025

MalarVx licenses HDT Bio’s repRNA/LION™ Technology for Novel Malaria Vaccine

16 January 2025

FDA approves Lilly’s Omvoh® (mirikizumab-mrkz) for Crohn’s disease, expanding its use to the second major type of inflammatory bowel disease

15 January 2025

Axcynsis Therapeutics Receives FDA Clearance for IND Application of AT03-65, a Differentiated CLDN6-Targeting ADC, Powered by AxcynDOT™ Technology

15 January 2025

Be Bio Announces Closing of $92M Series C Financing and Completes Transition to a Multi-Program, Clinical Stage Company

15 January 2025

OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma

15 January 2025

Chromatin Bioscience’s synthetic promoter supports EsoBiotec’s ESO-T01 CAR-T therapy as it enters the clinic

15 January 2025

Bayer’s Pharma Growth Strategy Progressing Well as Pipeline Advances

15 January 2025

Next Generation Gene Therapeutics (NGGT) Announces Publication of Early Clinical Trial Results for NGGT001 for the Treatment of Bietti’s Crystalline Dystrophy (BCD)

15 January 2025

Celltrion unveils strategic vision for advancing its innovative drug pipeline at the 43rd Annual J.P. Morgan Healthcare Conference

15 January 2025

Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76

14 January 2025

Bio-Thera Solutions Publishes Phase I Clinical Study Results for BAT4406F, an ADCC-Enhanced Fully Humanized Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorders

14 January 2025

FDA Clears Ariceum Therapeutics’ 225Ac-Satoreotide Phase I/II Clinical Study in Patients with Small Cell Lung Cancer or Merkel Cell Carcinoma

14 January 2025

Keylicon Biosciences Secures Exclusive Rights to Modified Self-Amplifying RNA Technology

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

2023 Sales of Antibodies & Proteins

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

GPC3-Targeted Immunotherapy Pipeline Review

B7-H4 Targeted Antibody Therapy Pipeline Review

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

DLL3-Targeted Immunotherapy Candidates Pipeline Review

EpCAM-Targeted Antibodies Pipeline Review

TL1A Inhibitor Pipeline Review

c-Met-Targeted Antibody Therapy Pipeline Review

Mesothelin-Targeted Immunotherapy Pipeline Review

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review

Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins